How Global Pharma Companies Navigate Uncertainty

The pharmaceutical industry operates across long development cycles, highly regulated manufacturing processes and international markets. A medicine may move through research, development, clinical evaluation, regulatory review, scale-up and commercial supply, with quality requirements applying at every stage. Changes in one market may therefore affect decisions made years earlier.

Demand also has its own complexity. Some medicines are needed steadily, while others respond to disease patterns, treatment protocols, seasonal requirements or changes in clinical practice. Manufacturers depend on raw materials, specialised equipment, skilled people, logistics providers and regulatory approvals that may span several countries.

These pressures are interconnected. A regulatory change may require process updates; a supplier disruption may affect production schedules; and higher input or freight costs may challenge product economics. Resilience is therefore a management capability connecting quality, operations, procurement, finance, commercial teams and leadership, rather than a single contingency plan.

Regulatory and Policy Change

Requirements evolve as authorities update expectations for product quality, data integrity, manufacturing controls, environmental performance and safety monitoring. Deloitte’s 2025 life sciences executive outlook found that 37% of respondents were apprehensive about global regulatory changes and geopolitical uncertainties, underlining the importance of monitoring developments across markets rather than treating compliance as a periodic exercise. [1]

Trade, Tariffs and Geopolitics

Trade measures, customs procedures and geopolitical shifts can alter the landed cost of materials and products, or change the relative attractiveness of manufacturing and sourcing locations. In a 2025 KPMG survey, 20% of life sciences respondents reported that current or potential tariffs were affecting contract manufacturing operations, illustrating that trade changes may reach beyond finished products into outsourced production. [2]

Supply Disruption and Input Costs

Manufacturers may face shortages or delays in active ingredients, intermediates, excipients, packaging components, utilities or specialist services. Input prices and lead times can change at different speeds, making supplier visibility, inventory decisions and technically and regulatorily qualified alternatives important parts of operational planning.

Pricing and Cost Pressure

Pricing expectations differ by market, customer and product, while the cost base includes quality systems, compliance, skilled labour, energy, technology and capital-intensive facilities. Companies must assess cost competitiveness without compromising product quality or making short-term savings that create greater operational exposure later.

A resilient pharmaceutical supply chain combines visibility with options. Depending on the product and its regulatory requirements, companies may use qualified alternative suppliers, appropriate safety stock, regional capacity, demand scenarios and regular reviews of critical materials. No single model suits every medicine: inventory has cost and shelf-life implications, while alternative sources or sites require technical assessment and formal qualification.

Supplier visibility is essential. Procurement and manufacturing teams need to understand not only a supplier’s price and delivery record, but also its upstream dependencies, quality performance, capacity constraints and exposure to transport or geopolitical disruption. Escalation routes and clear ownership help convert early warnings into decisions before a delay becomes a production issue.

Manufacturing networks also create options when capabilities, approvals and capacity are appropriately aligned. Piramal Pharma’s public facility directory identifies development and manufacturing operations across India, North America and Europe, with capabilities spanning APIs, formulations, sterile manufacturing and specialised products. [5] Geographic presence alone does not mean every product can be moved between sites: processes, equipment, technical knowledge and regulatory approvals determine what can be transferred.

An example of cross-site coordination is Piramal Pharma Solutions’ tablet-in-capsule programme announced in February 2026. Development began at its Ahmedabad site, followed by technology transfer to the commercial manufacturing site in Pithampur, completed within five months. The company said development, scale-up, technology transfer, quality control and validation teams worked across the two sites. [6] The example illustrates how integrated teams and established transfer processes can connect development knowledge with commercial manufacturing.

These choices are product-specific, and a company’s supply network should be judged by how well it matches capabilities to actual requirements. For a deeper look at the operating practices involved, read our article on building a resilient pharmaceutical supply chain and our perspective on vertical API integration.

Digital tools are most useful when they connect information teams need to make decisions. Shared data on orders, inventory, supplier status, manufacturing schedules, deviations and quality trends can help teams spot emerging issues earlier and compare options using a common view of operations. Technology still depends on reliable data, clear ownership and processes that turn signals into action.

Planning tools can also support scenario analysis: teams can test how changes in demand, lead times, cost or site availability might affect production and service. The aim is not to predict every event, but to make assumptions visible, identify decision points and agree who acts when conditions change.

Digital transformation across pharma is explored in our article on connecting people, processes and decisions. For the broader context of innovation across the sector, see our perspective on how pharma companies are shaping healthcare.

Investment in research and development also needs a long-term view. Development programmes have uncertain timelines and outcomes, but abrupt decisions made without considering scientific, customer and portfolio context may create downstream consequences. Disciplined portfolio reviews help organisations assess priorities while continuing to meet existing quality and supply responsibilities. See our article on innovation beyond the laboratory for a wider view of innovation across the value chain.